Solventum Co. (NYSE:SOLV) Receives Average Rating of “Hold” from Analysts

Solventum Co. (NYSE:SOLV) has been assigned a consensus rating of “Hold” from the eleven research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and one has assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $79.86.

Several research firms have recently commented on SOLV. Morgan Stanley lifted their price target on Solventum from $73.00 to $80.00 and gave the stock an “equal weight” rating in a report on Wednesday. Piper Sandler boosted their target price on shares of Solventum from $75.00 to $84.00 and gave the company a “neutral” rating in a report on Friday, February 28th. Bank of America raised their price target on shares of Solventum from $80.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, February 26th. Mizuho lifted their price target on shares of Solventum from $70.00 to $82.00 and gave the company a “neutral” rating in a research report on Monday. Finally, The Goldman Sachs Group increased their price objective on Solventum from $63.00 to $71.00 and gave the stock a “sell” rating in a research report on Monday.

Solventum Stock Performance

Shares of Solventum stock opened at $77.79 on Friday. The business’s 50 day moving average price is $73.25 and its 200 day moving average price is $70.39. The company has a market cap of $13.44 billion and a price-to-earnings ratio of 28.29. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.83 and a current ratio of 1.15. Solventum has a one year low of $47.16 and a one year high of $85.92.

Institutional Investors Weigh In On Solventum

Institutional investors have recently modified their holdings of the company. New York Life Investment Management LLC boosted its holdings in Solventum by 0.7% during the 4th quarter. New York Life Investment Management LLC now owns 18,506 shares of the company’s stock valued at $1,223,000 after acquiring an additional 136 shares during the period. Blue Trust Inc. boosted its stake in shares of Solventum by 2.1% in the fourth quarter. Blue Trust Inc. now owns 7,872 shares of the company’s stock valued at $549,000 after purchasing an additional 161 shares during the period. MML Investors Services LLC boosted its stake in shares of Solventum by 3.2% in the third quarter. MML Investors Services LLC now owns 5,345 shares of the company’s stock valued at $373,000 after purchasing an additional 168 shares during the period. EP Wealth Advisors LLC grew its holdings in shares of Solventum by 3.6% in the fourth quarter. EP Wealth Advisors LLC now owns 5,272 shares of the company’s stock valued at $348,000 after purchasing an additional 181 shares in the last quarter. Finally, Avantax Advisory Services Inc. increased its stake in Solventum by 2.2% during the 4th quarter. Avantax Advisory Services Inc. now owns 8,835 shares of the company’s stock worth $584,000 after buying an additional 192 shares during the period.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.